정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 772 | Completed | Proxalutamide Treatment for Hospitalized COVID-19 Patients | SARS (Severe Acute Respiratory Syndrome) | Drug: Proxalutamide Drug: Placebo |
Phase 3 | Applied Biology, Inc. | INDUSTRY | 645 | All | 18 Years | Hospital Regional Jose Mendes, Itacoatiara, Amazonas, Brazil Hospital de Campanha de Manacapuru, Manacapuru, Amazonas, Brazil Hospital Oscar Nicolau, Manaus, Amazonas, Brazil Hospital Prontocord, Manaus, Amazonas, Brazil Hospital Samel, Manaus, Amazonas, Brazil Hospital Regional Dr. Hamilton Maia Cidae, Manicore, Amazonas, Brazil Hospital Raimunda Francisca Dinelli da Silva, Maues, Amazonas, Brazil Hospital Regional Jofre Cohen, Parintins, Amazonas, Brazil |
| 771 | Active, not recruiting | PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 | Covid19 Vaccine | Biological: PTX-COVID19-B Biological: Placebo |
Phase 1 | Providence Therapeutics Holdings Inc. | INDUSTRY | 60 | All | 18 Years ~ 64 Years | Manna Research, Toronto, Ontario, Canada |
| 770 | Active, not recruiting | Public Health Emergency: SOLIDARITY TRIAL Philippines | Covid19 | Drug: Remdesivir Drug: Hydroxychloroquine Drug: Lopinavir / Ritonavir Drug: Interferon beta-1a Drug: Acalabrutinib |
Not Applicable | University of the Philippines | OTHER | 1314 | All | 18 Years | Baguio General Hospital, Baguio City, Benguet, Philippines Cebu Doctor's University Hospital, Cebu City, Cebu, Philippines Perpetual Succor Hospital Cebu, Cebu City, Cebu, Philippines Vicente Sotto Memorial Medical Center, Cebu City, Cebu, Philippines Southern Philippines Medical Center, Davao City, Davao, Philippines West Visayas University Medical Center, Iloilo City, Iloilo, Philippines Makati Medical Center, Makati City, Metro Manila, Philippines Chinese General Hospital, Manila, Metro Manila, Philippines Manila Doctors Hospital, Manila, Metro Manila, Philippines ManilaMed - Medical Center Philippines, Manila, Metro Manila, Philippines San Lazaro Hospital, Manila, Metro Manila, Philippines UP - Philippine General Hospital, Manila, Metro Manila, Philippines Asian Hospital and Medical Center, Muntinlupa, Metro Manila, Philippines Research Institute for Tropical Medicine, Muntinlupa, Metro Manila, Philippines San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines The Medical City, Pasig City, Metro Manila, Philippines Diliman Doctors Hospital, Quezon City, Metro Manila, Philippines Fe Del Mundo Medical Center, Quezon City, Metro Manila, Philippines Lung Center of the Philippines, Quezon City, Metro Manila, Philippines St Luke's Medical Center Quezon City, Quezon City, Metro Manila, Philippines University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines World Citi Medical Center, Quezon City, Metro Manila, Philippines Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines St Luke's Medical Center Global, Taguig, Metro Manila, Philippines Batangas Medical Center, Batangas, Philippines |
| 769 | Recruiting | Pulmozyme to Improve COVID-19 ARDS Outcomes | COVID | Drug: Pulmozyme Drug: Placebo |
Phase 2 | Boston Children's Hospital, Brigham and Women's Hospital | OTHER | 60 | All | 3 Years | Boston Children's Hospital, Boston, Massachusetts, United States Brigham and Women's Hospital, Boston, Massachusetts, United States |
| 768 | Completed | PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) | COVID-19 | Drug: Povidone-Iodine 2% Drug: Povidone-Iodine 0.5% Drug: Isotonic saline 0.9% |
Phase 2 | Stanford University | OTHER | 47 | All | 18 Years | Stanford Health Care, Stanford, California, United States |
| 767 | Recruiting | Pyridostigmine in Severe SARS-CoV-2 Infection | SARS-CoV-2 | Drug: Pyridostigmine Bromide Drug: Placebo |
Phase 3 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | OTHER | 436 | All | 18 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Tlalpan, Mexico |
| 766 | Recruiting | Quercetin In The Treatment Of SARS-COV 2 | SARS (Severe Acute Respiratory Syndrome) | Drug: Quercetin Drug: Placebo |
Early Phase 1 | Hopital Universitaire Sahloul | OTHER | 200 | All | 18 Years | HU Sahloul, sousse, Tunisia, Sousse, Itineraire Ceinture Cite Sahloul, Tunisia Riadh Boukef, Sahloul, Sousse, Tunisia |